DF/HCC Clinical Research Community,

We are pleased to announce that Nareg Grigorian has been named as the new Director, Office of Data Quality supporting clinical research across Dana-Farber/Harvard Cancer Center. Nareg’s many years of service, and his in-depth working knowledge within the Office of Data Quality and across the DF/HCC Consortium, will serve him and the department well as we embark on the next phase of our work together.

Nareg Grigorian

Nareg brings more than thirteen years of experience working collaboratively across DF/HCC. He joined the department in 2011 as Manager, Internal Auditing Program and more recently served as the Associate Director, Data Safety Monitoring where he oversaw clinical trials data and safety monitoring functions, ensuring compliance with the Cancer Center Support Grant and the DF/HCC Data and Safety Monitoring Plan (DSMP). His responsibilities have included managing the DF/HCC Internal Auditing Program, the DF/HCC Audit Committee, and overseeing the DF/HCC Data and Safety Monitoring Board (DSMB), and two Data and Safety Monitoring Committees (DSMCs). Nareg has mentored and developed staff within the Auditing Team while acting as a subject matter expert to the DF/HCC Research Community and Oversight Committees. Nareg has also served on two DFCI IRB panels throughout his tenure. He holds a Master of Science in Bioethics with a concentration in Clinical Research from The Mount Sinai Icahn School of Medicine & Union Graduate College, and a Graduate Certificate in Global Public Health from the Gillings School at UNC.

In his new role, Nareg will co-lead the DF/HCC Clinical Operations Committee jointly with Sarah Kiskaddon, and will be responsible for the day-to-day operations of ODQ including: study activation, ct.gov reporting, audit, data safety monitoring, and investigator-sponsored data integrity. 

Please join us in congratulating Nareg on this well-deserved appointment as our new Director.

Sincerely,

Rebecca Heist, MD
Associate Professor of Medicine at Harvard Medical School
Director, Clinical Trials, DF/HCC
Lee Albright and Nile Albright MD Endowed Chair in Clinical Cancer Research,
Massachusetts General Hospital

Jeffrey Meyerhardt, MD, MPH, FASCO
Professor of Medicine, Harvard Medical School
Associate Director, Clinical Trials, DF/HCC
Douglas Gray Woodruff Chair in Colorectal Cancer Research,
Chief Clinical Research Officer,
Dana-Farber Cancer Institute

Kyle Bird, MHA
VP, Clinical Research Management
Dana-Farber Cancer Institute
Dana-Farber/Harvard Cancer Center